Expired activity
Please go to the PowerPak homepage and select a course.

Three Challenging Cases in the Diagnosis and Management of Invasive Fungal Infections

Jointly presented by: The Johns Hopkins University School of Medicine and Postgraduate Healthcare Education, LLC

Acknowledgement of Commercial Support: Supported by independent educational grants from Astellas and Merck.


Paul G. Auwaerter, MD, MBA, FACP, FIDSA
Clinical Director, Division of Infectious Diseases
Sherrilyn and Ken Fisher Professor of Medicine
Johns Hopkins University School of Medicine
Chief Medical Officer, Point of Care-Information Technology (POC-IT) Center
Johns Hopkins University School of Medicine

Michael A. Chattergoon, MD, PhD
Assistant Professor
Division of Infectious Diseases
Johns Hopkins University School of Medicine
Johns Hopkins AIDS Service


No faculty members have indicated that they have any financial interests or relationships with a commercial entity whose products or services are relevant to the content of their presentations.

The following reviewer, Kyle J. Wilby, BSP, ACPR, PharmD,has no actual or potential conflict of interest in relation to this program.

Michael Speidel, Medical Logix, LLC hereby states he does not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Susanne Batesko, RN, BSN, Michele Salernitano, and Robin Carrino, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. We are committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.


acpePostgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0430-0000-16-014-H01-P
1.5 hours (0.15 ceu)

Published: March 15, 2016
Expires: March 21, 2017
Type of Activity: Knowledge
Media: Internet

Fee Information: There is no fee for this educational activity.

Estimated time to complete activity: 90 minutes


This accredited activity has been designed for pharmacists.


During the period March 15, 2016 through March 21, 2017, participants must 1) read the educational objectives and faculty disclosures; 2) study the educational activity; and 3) complete the posttest and the evaluation form. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on 'Submit Posttest' at the bottom of the page. Your posttest will automatically be graded. If you successfully complete the posttest (score of 70% or higher), your Statement of Credit will be made available immediately. Click on View Certificate and print the Statement of Credit for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest.


This activity is designed to inform and educate pharmacy professionals about the diagnosis and treatment of fungal infections.


Upon completion of this activity, participants should be better able to:

  1. Describe the epidemiology of common invasive fungal infections (IFI).
  2. Assess and stratify patients into appropriate risk groups.
  3. Outline the benefits and limitations of available tools for early diagnosis of IFI to select appropriate diagnostic methods.
  4. Design optimal management strategies for candidiasis, cryptococcosis and aspergillosis based on the current IDSA guidelines, particularly in immunocompromised and immunosuppressed patients, including the possible roles of prophylactic, preemptive, and empiric treatments.
  5. Apply knowledge of the mechanism of action of antifungal agents, the potential for drug-drug interactions, and potential combination regimens for common IFI to treatment planning and prophylaxis.
  6. Use appropriate therapeutic drug monitoring for patients on antifungals.


Please ensure the computer you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac &/ Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft Powerpoint, Flash Player & HTML5


The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC, Astellas and Merck. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.

The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsors promote the use of any agent outside of approved labeling. Statements made in this activity have not been evaluated by the FDA. Nutritional products discussed are not intended for the diagnosis, treatment, cure, or prevention of any disease.

eCase Challenge Program Description

eCase Challenges are text-based case programs where pharmacists are presented with challenging case scenarios and are asked to make patient management recommendations.

This eCase Challenge is in the form of a transcript. References for transcript in its entirety are available upon request.